

New Skin Substitute Policies-Effective September 17, 2023

August 10, 2023

On August 3, Novitas, First Coast Service Options, and CGS Part B Medicare Administrative Contractors (MAC) finalized skin substitute policies for the treatment of diabetic foot ulcers (DFC's) and venous leg ulcers (VLU's) that become effective September 17, 2023.

The policies state **"greater than four applications of a skin substitute graft or CTP within the episode of skin replacement surgery** (defined as 12 weeks from the first application of a skin substitute graft or CTP)" **are "not medically reasonable and necessary."** Additionally, these policies list 58 products that meet the necessary FDA regulatory requirements for indications covered in the policy (**see attachment**) and 130 products that are considered non-covered (**see attachment**).

The <u>Novitas Part B Jurisdiction</u> includes AR, CO, DE, LA, MD, MS, NJ, NM, OK, PA, TX, and Washington, DC

The <u>First Coast Service Options</u> Part B Jurisdiction includes FL, Puerto Rico, and the Virgin Islands.

The <u>CGS Part B Jurisdiction</u> includes KY and OH. These policies are final. Changes were initially proposed by Novitas and First Coast in April 2022 and by CGS in October 2022.

Reference: APMA, Novitas